Leo Lens Pharma Strengthens its Pipeline with New IP Protection for a Unique Atropine-based Myopia Management Solution

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Leo Lens Pharma (formerly DBA as Leo Lens Technology Co., Inc.) has announced it received a notice of allowance from the USPTO for a patent for the use of its proprietary MediPrint™ process to manufacture a contact lens capable of providing enhanced myopia management.

The novel product will allow patients suffering from, or at a high risk of developing, myopia to wear a contact lens that can automatically and continuously deliver a drug to control myopia, such as low dose Atropine, to the patient’s eye. The MediPrint™ process is compatible with a variety of base contact lenses, allowing Leo Lens Pharma to pair its drug delivery technology with contact lenses designed to help slow the progression of myopia.

The use of contact lens in myopia management is not new. As the stigma of wearing glasses or spectacles leads children with myopia to look for alternatives, contact lens manufacturers have developed lenses to help slow the progression of myopia. Leo Lens Pharma aims to be the first company to pair contact lenses with the continuous delivery of drugs shown to help with myopia management.

“Myopia is a growing epidemic affecting over 2.5B people globally and we are excited to be working on a solution that could have a beneficial impact to a growing number of young patients with myopia globally,” said Praful Doshi, Founder and CTO. “Fortunately, this patent and development effort will benefit from the learnings out of our more immediate focus to help protect sight in the glaucoma market with a weekly continuous dosing therapy made possible by our unique MediPrint™ process.”

While this new patent expands Leo Lens Pharma’s IP portfolio, the Company’s lead proprietary asset is a lens to treat glaucoma. This lens is manufactured with the MediPrint™ process, which allows for the continuous release of FDA approved Bimatoprost. Considering the millions of glaucoma patients diagnosed and treated in the U.S. alone, and the countless others who are undiagnosed or untreated currently, the advent of Leo Lens Pharma’s complete solution for glaucoma treatment will benefit patients and eye care professionals alike. Leo Lens Pharma has already had a successful pre-IND meeting with the FDA to confirm its regulatory strategy and will soon be submitting an IND for a Phase 2a clinical trial with the glaucoma product.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.